The antibiotic Zithromax, Zmax (azithromycin) should not be given long-term to prevent a certain inflammatory lung condition in patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant. Results of a clinical trial found an increased rate of relapse in cancers affecting the blood and lymph nodes, including death, in these patients.
Zithromax, Zmax (azithromycin): FDA Warning – Increased Risk of Cancer Relapse With Long-Term Use After Donor Stem Cell Transplant
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA In Brief: FDA Publishes Material Safety Data to Promote Safer, More Effective Medical Devices
- FDA Issues Draft Guidance on Donor Eligibility and Manufacturing of Cellular Therapies for Animals
- FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations
- Cordis Recalls SUPER TORQUE MB Angiographic Catheter with Radiopaque Marker Bands Due to Potential for Marker Bands to Move or Dislodge